New hope for kids with brittle bones: experimental drug takes on standard therapy
NCT ID NCT06079372
First seen Nov 14, 2025 · Last updated May 22, 2026 · Updated 22 times
Summary
This study tests a new medicine, ALXN1850, against the current standard treatment (asfotase alfa) in 43 children aged 2 to 12 with hypophosphatasia, a rare genetic condition that weakens bones. All children have been on the standard treatment for at least 6 months before joining. The main goal is to see if the new drug is safe and tolerable, with secondary goals including improvements in bone health, walking ability, and growth. The study is active but not recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPHOSPHATASIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Hartford, Connecticut, 06106, United States
-
Research Site
Baltimore, Maryland, 21287, United States
-
Research Site
Minneapolis, Minnesota, 55455, United States
-
Research Site
Kansas City, Missouri, 64108, United States
-
Research Site
Durham, North Carolina, 27705, United States
-
Research Site
Nashville, Tennessee, 37212, United States
-
Research Site
Mar del Plata, B7600, Argentina
-
Research Site
South Brisbane, 4101, Australia
-
Research Site
Ottawa, Ontario, K1H 8L1, Canada
-
Research Site
Bunkyō City, 113-8431, Japan
-
Research Site
Minatoku, 105-8471, Japan
-
Research Site
Suita-shi, 565-0871, Japan
-
Research Site
Yonago-shi, 683-8504, Japan
-
Research Site
Altındağ, 06230, Turkey (Türkiye)
-
Research Site
Ankara, 06560, Turkey (Türkiye)
-
Research Site
Edirne, 22030, Turkey (Türkiye)
-
Research Site
Erzurum, 25240, Turkey (Türkiye)
-
Research Site
Istanbul, 34899, Turkey (Türkiye)
-
Research Site
Birmingham, B4 6NH, United Kingdom
-
Research Site
Manchester, United Kingdom
-
Research Site
Sheffield, S10 2TH, United Kingdom
Conditions
Explore the condition pages connected to this study.